A highly anticipated clinical trial from Eli Lilly showed its Type 2 diabetes drug met its primary endpoints. CNBC’s Meg Tirrell joins ‘Squawk Box’ to break down the results.
Eli Lilly drug tirzepatide meets weight-loss goals in obesity trial
Tweet on Twitter
Share on Facebook
Pinterest
